The European Medicines Agency (EMA) is reviewing possible links between Johnson & Johnson’s COVID-19 vaccine and blood clots.
One case involved a person in a clinical trial, and the three others happened during the US rollout of the vaccine. In one of the cases, the person died, the release said.
The J&J COVID-19 vaccine was authorised for use in the European Union on March 11, but the vaccines have not yet been rolled out there. The EU rollout is supposed to start in the next few weeks. Only the US is currently seeing a supply of J&J vaccines.
The Pandemic Response Accountability Committee is reviewing the blood clot cases and will announce what it has found once the investigation is complete.
In an official statement, Johnson & Johnson said that the company is “aware” that there have been thromboembolic events (blood clots) “reported with all COVID-19 vaccines.”
J&J said that it is working closely with experts and regulators to take a closer look at the data.
The company said people who get the COVID-19 vaccine and experience any severe symptoms should seek medical assistance immediately.
Symptoms could include shortness of breath, chest pain, swelling in the leg, persistent belly pain, neurological symptoms, excessive or easy bruising, or tiny blood spots under the skin beyond the site of injection.